On November 11, 2020 DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical stage biopharmaceutical company developing novel treatments for chronic kidney diseases and neurological disorders, reported its President and CEO, Rick Pauls, and Chief Financial Officer, Scott Kellen, are scheduled to participate in the Craig-Hallum Alpha Select Conference, which is being held as a virtual event on November 17, 2020 (Press release, DiaMedica, NOV 11, 2020, https://ir.diamedica.com/news/detail/1605/diamedica-therapeutics-to-participate-in-11th-annual-craig-hallum-alpha-select-conference [SID1234570567]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Meetings will take place virtually on November 17, 2020 given the ongoing call for social distancing due to the Covid-19 pandemic. Interested institutional investors should contact their Craig-Hallum sales representative to schedule a meeting.